Armas Pharmaceuticals Incorporated, a New Jersey based multisource pharmaceutical corporation, is launching its first injectable, Azacitidine for Injection 100 MG, in the United States, it was reported yesterday.

The product is used for treating myelodysplastic syndrome, a form of cancer that leads to one or more blood cell types dropping to low numbers. It is an oncology injectable. The company aims to launch nine or more generic injectable and oral products by the first quarter of 2019, with a market size totalling more than USD430m per annum.

John Niemi, president & CEO of Armas, said, 'We are pleased to launch our first product in the US market. This will be the first of a number of high-quality pharmaceutical products that we will launch in the Armas Pharmaceutical label through our partnerships. With Armas's strong customer base and our outstanding partners, I have no doubt that Armas Pharmaceuticals will bring exceptional value with our upcoming product launches to healthcare professionals.'